EMA Authorised: Izamby (denosumab) — Mabxience Research SL

View source ↗

Summary

The EMA authorised Izamby (denosumab) for osteoporosis-related bone resorption disorders, including postmenopausal osteoporosis, with Mabxience Research SL as t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Izamby (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Mabxience Research SL. Decision date: 20/11/2025